VRC 607-ACTG A5378: A Phase 1, Single Dose Study of the Safety and Virologic Effect of an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) or VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously to HIV-Infected Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TMB-380 (Primary) ; VRC 01LS (Primary)
Indications HIV-1 infections
Focus Adverse reactions
Acronyms VRC607-ACTG-A5378

Most Recent Events

16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections
28 Jan 2020 Status changed from active, no longer recruiting to completed.
10 May 2019 Planned End Date changed from 31 Mar 2020 to 28 Feb 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight